904 results on '"Benson, Don M"'
Search Results
2. Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
3. Racial differences as predictors of outcomes in young patients with multiple myeloma
4. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
5. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up
6. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma
7. Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
8. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
9. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant
10. Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
11. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas
12. Improvement in survival of acute myeloid leukemia and myelodysplastic syndrome patients following allogeneic transplant: a long-term institutional experience
13. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
14. The IL-15–AKT–XBP1s signaling pathway contributes to effector functions and survival in human NK cells
15. Ninety-minute daratumumab infusion is safe in multiple myeloma
16. TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma
17. Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells
18. Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease
19. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
20. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
21. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma
22. Supplementary Figures S1-S4 with Legends from Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
23. Figure S2 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
24. Data from The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
25. Data from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
26. Data from Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
27. Supplementary Data from The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
28. Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
29. Supplementary Materials and Methods from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells
30. Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
31. Supplementary Figure S1-S15 from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells
32. supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
33. Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
34. The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells
35. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
36. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
37. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
38. Contributors
39. Natural Killer Cell Immunity
40. Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
41. Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
42. T-Cell Senescence and Exhaustion Are Associated with Interval Progression of Multiple Myeloma before Autologous Hematopoietic Cell Transplant
43. Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race
44. The Co-Occurrence of 1q21+/1q23+ and t(4;14) Abnormalities with Specific Clone Size Is Predictive of Shorter Response to Transplant in Patients with Multiple Myeloma
45. Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience
46. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
47. Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
48. MicroRNAs activate natural killer cells through Toll-like receptor signaling
49. Chunking, Rule Learning, and Multiple Item Memory in Rat Interleaved Serial Pattern Learning
50. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.